Rubicon Research is a pharmaceutical formulations company, driven by innovation through focused research and development, with an increasing portfolio of specialty products and drug-device combination products targeting regulated markets.
About Us
Innovative Solutions
in Medicines
As of March 31, 2024, Rubicon Research had 55 commercialized products in the US. Across its 69 active NDAs and ANDAs, Rubicon Research has widened its portfolio of formulations by including oral capsules, concentrates, solutions, suspensions, syrups, tablets; ophthalmic drops; and intrathecal injections. Rubicon Research has also added advanced formulations like the delayed and extended - release tablets and drug-device combination of nasal spray. In the year 2023, Rubicon Research received one of the seven nasal spray ANDA and NDA approvals granted by the FDA.
Read MorePRODUCTS
High Quality Generic
and Specialty Products
Our proprietary technologies are backed by 10 patents in various countries including India and the US, which we can leverage for the development of value-added specialty products.
Read MoreRubicon Research’s well-designed and well-equipped R&D labs and cGMP compliant manufacturing plant reflect our focus on innovation, excellence, and process improvements.
Read MoreCharting our success
69
Approved products in the US
250 +
SKUs launched in US
3 +
Billion extended units sold in the US (2023)
80 +
Products in the pipeline
50 +
Patents in drug delivery technologies
10
Proprietary drug delivery technologies
19
Patents Granted
61
Registered Trademarks
40 +
Product Candidates in various stages in development
Partner with Us
Partnering Is A Priority
We believe that our product development capabilities backed by experience in navigating regulatory pathways, large - scale commercial manufacturing and marketing capabilities for branded and non-branded products uniquely position us as a co-development and commercialization partner for early-stage and pre-clinical stage companies.
Read More